Safety and Efficacy of Topically Applied CTA018 in Plaque Psoriasis
Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
Vitamin D and its analogs are currently widely used for the treatment of psoriasis. The study
drug (CTA018) is a novel analog of vitamin D, and this Phase 2 study will investigate the
efficacy and safety of CTA018 in the treatment of psoriasis. Patients with chronic plaque
psoriasis will receive one of three doses of CTA018 cream or vehicle (no study drug) daily
for 12 weeks.